Compare Elanco Animal Health, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 12,074 Million (Small Cap)
14.00
NA
0.00%
0.52
1.65%
1.79
Revenue and Profits:
Net Sales:
1,241 Million
(Quarterly Results - Jun 2025)
Net Profit:
11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.55%
0%
12.55%
6 Months
71.2%
0%
71.2%
1 Year
102.08%
0%
102.08%
2 Years
52.89%
0%
52.89%
3 Years
75.27%
0%
75.27%
4 Years
-2.64%
0%
-2.64%
5 Years
-14.34%
0%
-14.34%
Elanco Animal Health, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.86%
EBIT Growth (5y)
-0.48%
EBIT to Interest (avg)
0.90
Debt to EBITDA (avg)
5.95
Net Debt to Equity (avg)
0.62
Sales to Capital Employed (avg)
0.39
Tax Ratio
30.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2.12%
ROE (avg)
2.44%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.09
EV to EBIT
45.24
EV to EBITDA
12.07
EV to Capital Employed
1.05
EV to Sales
2.44
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
2.33%
ROE (Latest)
8.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 87 Schemes (68.26%)
Foreign Institutions
Held by 169 Foreign Institutions (16.88%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,241.00
1,193.00
4.02%
Operating Profit (PBDIT) excl Other Income
254.00
282.00
-9.93%
Interest
70.00
53.00
32.08%
Exceptional Items
8.00
-24.00
133.33%
Consolidate Net Profit
11.00
67.00
-83.58%
Operating Profit Margin (Excl OI)
68.50%
101.40%
-3.29%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 4.02% vs 16.96% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -83.58% vs 937.50% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,439.00
4,417.00
0.50%
Operating Profit (PBDIT) excl Other Income
913.00
1,020.00
-10.49%
Interest
339.00
277.00
22.38%
Exceptional Items
-172.00
-1,162.00
85.20%
Consolidate Net Profit
338.00
-1,231.00
127.46%
Operating Profit Margin (Excl OI)
56.50%
73.80%
-1.73%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.50% vs 0.14% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 127.46% vs -1,478.21% in Dec 2023
About Elanco Animal Health, Inc. 
Elanco Animal Health, Inc.
Pharmaceuticals & Biotechnology
Elanco Animal Health Incorporated is an animal health company that develops, manufactures and markets products for companion and food animals. The Company offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. It provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. It also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. It also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. It also provides products in poultry and aquaculture production.
Company Coordinates 
Company Details
2500 Innovation Way N , GREENFIELD IN : 46140-9163
Registrar Details






